GMDAQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GMDAQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Gamida Cell's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was -74.28%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Gamida Cell's 5-Year ROIIC % or its related term are showing as below:
The historical data trend for Gamida Cell's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gamida Cell Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
5-Year ROIIC % | Get a 7-Day Free Trial | - | - | -121.73 | -98.04 | -74.28 |
Gamida Cell Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
5-Year ROIIC % | Get a 7-Day Free Trial | -98.04 | - | - | - | -74.28 |
For the Biotechnology subindustry, Gamida Cell's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Gamida Cell's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Gamida Cell's 5-Year ROIIC % falls into.
Gamida Cell's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:
5-Year ROIIC % | = | 5-Year Incremental Net Operating Profit After Taxes (NOPAT)** | / | 5-Year Incremental Invested Capital** |
= | ( -72.643 (Dec. 2023) - -33.6877372 (Dec. 2018) ) | / | ( 55.415 (Dec. 2023) - 2.973 (Dec. 2018) ) | |
= | -38.9552628 | / | 52.442 | |
= | -74.28%*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Gamida Cell (OTCPK:GMDAQ) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Thank you for viewing the detailed overview of Gamida Cell's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeremy Blank | director | 6446 DREXEL AVENUE, LOS ANGELES CA 90048 |
Mary Theresa Coelho | officer: Chief Financial Officer | 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017 |
Ronit Simantov | officer: CMO & Chief Scientific Officer | 1988 CHAPEL STREET, NEW HAVEN CT 06515 |
Abigail L. Jenkins | director, officer: President and CEO | C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116 |
Stephen T Wills | director | PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Ivan M. Borrello | director | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
Anat Cohen-dayag | director | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
Naama Halevi-davidov | director | C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003 |
Joshua F. Patterson | officer: General Counsel | C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210 |
Bio Medical Investment (1997) Ltd. | other: Affiliate of 10% Owner | 3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301 |
Shai Lankry | officer: Chief Financial Officer | C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340 |
Ai Gamida Holdings Llc | other: Affiliate of 10% Owner | 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019 |
Ofer Gonen | director | 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102 |
Clal Biotechnology Industries Ltd. | other: Affiliate of 10% Owner | 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023 |
Len Blavatnik | 10 percent owner | C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019 |
From GuruFocus
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 03-28-2024
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.